Prothena Corp

PRTA

Market cap $529M

Overview Fund Trends Analyst Outlook Journalist POV

9.82 USD

+0.07

0.72%

At close Updated Oct 24, 4:00 PM EDT

Pre-market

After hours

9.42

--0.40

4.07%

1 day

0.72%

5 days

-2.29%

1 month

5.36%

3 months

46.57%

6 months

1.76%

Year to date

-28.16%

1 year

-39.64%

5 years

-13.48%

10 years

-80.4%

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163

Healthcare Biotechnology